Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells

M. Carapeti, R. C T Aguiar, H. Sill, J. M. Goldman, N. C P Cross

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid leukaemia, CML, in chronic phase or blast crisis, n = 71; de novo acute leukaemia, n = 26) and 16 normal individuals. Intact FHIT transcripts from all cases were amplified using RT-PCR. In addition, smaller size bands that were less intense than the full-length products were amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in the coding sequence were detected in any patient. Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis. Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of an abnormality in the absence of demonstrable genomic DNA lesions.

Original languageEnglish (US)
Pages (from-to)601-605
Number of pages5
JournalBritish Journal of Cancer
Volume78
Issue number5
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Leukemia
Blast Crisis
Genes
Exons
Loss of Heterozygosity
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tumor Suppressor Genes
Leukocytes
Polymerase Chain Reaction
Mutation
DNA
Neoplasms

Keywords

  • 3p14.2
  • FHIT
  • FRA3B
  • Leukaemia
  • Loss of heterozygosity
  • Tumour-suppressor gene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. / Carapeti, M.; Aguiar, R. C T; Sill, H.; Goldman, J. M.; Cross, N. C P.

In: British Journal of Cancer, Vol. 78, No. 5, 09.1998, p. 601-605.

Research output: Contribution to journalArticle

Carapeti, M. ; Aguiar, R. C T ; Sill, H. ; Goldman, J. M. ; Cross, N. C P. / Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells. In: British Journal of Cancer. 1998 ; Vol. 78, No. 5. pp. 601-605.
@article{359b23540d5543b7bb36ba562b91ea82,
title = "Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells",
abstract = "Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid leukaemia, CML, in chronic phase or blast crisis, n = 71; de novo acute leukaemia, n = 26) and 16 normal individuals. Intact FHIT transcripts from all cases were amplified using RT-PCR. In addition, smaller size bands that were less intense than the full-length products were amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in the coding sequence were detected in any patient. Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis. Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of an abnormality in the absence of demonstrable genomic DNA lesions.",
keywords = "3p14.2, FHIT, FRA3B, Leukaemia, Loss of heterozygosity, Tumour-suppressor gene",
author = "M. Carapeti and Aguiar, {R. C T} and H. Sill and Goldman, {J. M.} and Cross, {N. C P}",
year = "1998",
month = "9",
language = "English (US)",
volume = "78",
pages = "601--605",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells

AU - Carapeti, M.

AU - Aguiar, R. C T

AU - Sill, H.

AU - Goldman, J. M.

AU - Cross, N. C P

PY - 1998/9

Y1 - 1998/9

N2 - Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid leukaemia, CML, in chronic phase or blast crisis, n = 71; de novo acute leukaemia, n = 26) and 16 normal individuals. Intact FHIT transcripts from all cases were amplified using RT-PCR. In addition, smaller size bands that were less intense than the full-length products were amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in the coding sequence were detected in any patient. Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis. Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of an abnormality in the absence of demonstrable genomic DNA lesions.

AB - Deletions and apparent transcriptional abnormalities of the FHIT gene at 3p14.2 have recently been reported in a wide variety of solid tumours. To determine whether lesions of this gene also occur in leukaemia, we have analysed a total of 97 patients (chronic myeloid leukaemia, CML, in chronic phase or blast crisis, n = 71; de novo acute leukaemia, n = 26) and 16 normal individuals. Intact FHIT transcripts from all cases were amplified using RT-PCR. In addition, smaller size bands that were less intense than the full-length products were amplified from several samples from patients with leukaemia and also from normal leucocytes. Sequencing of the small products revealed that they were derived from FHIT transcripts lacking whole exons. Using single-strand conformation polymorphism analysis, no mutations in the coding sequence were detected in any patient. Furthermore, loss of heterozygosity was not seen in any of 36 informative patients at D3S1300 or D3S1481, markers located within the FHIT locus. We conclude that the FHIT gene and other uncharacterized tumour-suppressor genes at 3p14.2 are unlikely to be involved in the pathogenesis of acute leukaemia or progression of CML from chronic phase to blast crisis. Moreover, low-abundance FHIT transcripts that lack whole exons are not specific to malignant cells and should not be taken as evidence of an abnormality in the absence of demonstrable genomic DNA lesions.

KW - 3p14.2

KW - FHIT

KW - FRA3B

KW - Leukaemia

KW - Loss of heterozygosity

KW - Tumour-suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=0031927129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031927129&partnerID=8YFLogxK

M3 - Article

C2 - 9744498

AN - SCOPUS:0031927129

VL - 78

SP - 601

EP - 605

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -